Eli Lilly and Company (LLY)vsMesoblast Ltd (MESO)
LLY
Eli Lilly and Company
$1,183.46
+0.13%
HEALTHCARE · Cap: $1.03T
MESO
Mesoblast Ltd
$15.12
-2.33%
HEALTHCARE · Cap: $2.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 66150% more annual revenue ($79.67B vs $120.25M). LLY leads profitability with a 33.5% profit margin vs -47.8%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
MESO
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+68.5%
Fair Value
$58.14
Current Price
$15.12
$43.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 390.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.1x book value
0.0% earnings growth
ROE of -18.2% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : MESO
The strongest argument for MESO centers on Revenue Growth, Debt/Equity. Revenue growth of 390.7% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : MESO
The primary concerns for MESO are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
LLY profiles as a growth stock while MESO is a hypergrowth play — different risk/reward profiles.
MESO carries more volatility with a beta of 0.82 — expect wider price swings.
MESO is growing revenue faster at 390.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 26/100), backed by strong 33.5% margins and 47.7% revenue growth. MESO offers better value entry with a 68.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Mesoblast Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?